Drugs / Treamid
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04428593 | Jan → Nov 2016 | metabolic syndrome X | PHARMENTERPRISES LLC | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04527354 | Sep 2020 → Feb 2021 | COVID-19, pulmonary fibrosis | PHARMENTERPRISES LLC | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05516550 | Aug → Dec 2022 | COVID-19, pulmonary fibrosis | PHARMENTERPRISES LLC | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Treamid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04527354 ↗ |
| Known as | XC268BG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095199 ↗ |
| Modality | Small molecule | — CHEMBL5095199 ↗ |
| Route | Oral | “after single and repeated oral administration” NCT04428593 ↗ |